Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESS RELEASE - EyePoint Pharmaceuticals, Inc. | dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 3, 2011
PSIVIDA CORP.
(Exact name of Registrant as specified in its charter)
| Delaware | 000-51122 | 26-2774444 | ||
| (State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
400 Pleasant Street
Watertown, MA 02472
(Address of Principal Executive Offices) (Zip Code)
(617) 926-5000
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On May 3, 2011, pSivida Corp. issued a press release announcing the presentation at the 2011 ARVO Annual Meeting of new data from the completed 36-month FAME™ Study of ILUVIEN® for the treatment of Diabetic Macular Edema (DME) sponsored by pSivida’s licensee, Alimera Sciences, Inc. pSivida’s press release and slides presented at the ARVO meeting are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
| (d) | Exhibits |
| Exhibit |
Description | |
| 99.1 | Press Release of pSivida Corp. dated May 3, 2011. | |
| 99.2 | Slides of Andrew N. Antoszyk, MD presented May 3, 2011 at the 2011 ARVO Annual Meeting incorporated by reference to Exhibit 99.1 of Form 8-K of Alimera Sciences, Inc. furnished to the SEC on May 3, 2011. | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| pSivida Corp. | ||||
| By: | /s/ LORI FREEDMAN | |||
| Name: | Lori Freedman | |||
| Title: | Vice President Corporate Affairs, General Counsel & Secretary | |||
| Dated: May 3, 2011 | ||||